Search results
In recent years, the antibody Mindbomb Homolog-1 (MIB-1) has evolved as a measure of the proliferative nature of the glial tumors. This study aims to investigate the MIB-1 index value as an independent prognostic factor in high-grade gliomas and its correlation with outcome and survival.
- FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in ...
A scoring system (“FORGE”) based on sex, peritumoral edema,...
- FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in ...
21 wrz 2013 · The MIB-1 labeling index, 4 which is based on Ki67 immunostaining, is widely used for evaluating the proliferation of tumor cells, because the mAb Ki67 reacts with an undefined antigen present in the nuclei of cells in all cell cycle phases, except G 0.
1 gru 2015 · MIB-1 is a DNA-binding nuclear protein expressed throughout the cell cycle in proliferating but not in quiescent (G0) cells. MIB-1 labeling index (LI) is measured to evaluate a malignant potential of tumors. The purpose of our study is to develop its prognostic and predictive role.
9 wrz 2021 · The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J. Neurooncol. 98, 41–47.
20 lip 2021 · A scoring system (“FORGE”) based on sex, peritumoral edema, preoperative CRP value, and plasma fibrinogen level supports prediction of the MIB-1 index (sensitivity 62%, specificity 79%). The MIB-1 labeling index and the FORGE score are significantly associated with an increased risk of poor PFS time.
27 sie 2020 · These include the MIB-1 index (a marker of cell proliferation), brain invasion, and the presence of atypical histologic features, including increased cellularity, sheeting, foci of spontaneous necrosis, and nuclear atypia (9 – 13).
16 lis 2012 · The MIB-1 labeling index, based on the Ki67 immunostaining, is widely used for evaluating the proliferation of tumor cells. We retrospectively evaluated the prognostic impact of the MIB-1 labeling index at diagnosis in patients with FL treated with rituximab plus cyclophosphamide, doxorubicine, vincristine, and prednisolone (R-CHOP) alone.
